By reporting this case of a SLC5A2 mutation functioning as a SGLT2 inhibitor, we hope to demonstrate the advantages and disadvantages of this drug for T1DM treatment in young children. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.